Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : Kevin Young CBE, Gilead's Chief Operating Officer, to Retire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 06:02pm CET

By a News Reporter-Staff News Editor at Pharma Business Week -- Gilead Sciences, Inc. (Nasdaq: GILD) announced that Kevin Young CBE, Chief Operating Officer, plans to retire, effective early 2018. Mr. Young will remain with Gilead through the first quarter of next year and in an advisory capacity thereafter (see also Pharmaceutical Companies).

Mr. Young joined Gilead in 2004 to lead the company's worldwide commercial operations. He oversaw the introduction of multiple new products, including the first single tablet regimens for HIV and the first oral direct acting antiviral regimens for chronic hepatitis C. In 2014, Mr. Young retired from his full-time role and served as a senior advisor to Gilead until 2016, when he returned to assume the role of Chief Operating Officer. Prior to Gilead, he spent more than 20 years in the biopharmaceutical industry, first with ICI Pharmaceuticals and subsequently with Amgen. Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise Physiology from Liverpool and Nottingham, England. In 2011, he was appointed a Commander of The British Empire, one of Great Britain's highest civilian honors, in recognition of his "services to the healthcare and pharmaceutical industries."

"Since Kevin joined Gilead in 2004, he has worked tirelessly to build Gilead's commercial success across numerous therapeutic areas and geographies," said John Martin, PhD, Executive Chairman. "Together with the Board of Directors, I am grateful that he came out of semi-retirement in May 2016 to strengthen Gilead and help establish the strategy and execute on plans for our next phase of growth in cell therapy."

"Kevin has had an impact on Gilead - and by extension on the field of medicine and the lives of patients - that is seldom seen," said John Milligan, PhD, President and Chief Executive Officer. "Those who have had the opportunity to work alongside Kevin know that he possesses both a deep commitment to his work and unparalleled leadership abilities. I am delighted that he will be helping us manage through a period of change over the next several months and I am deeply grateful to Kevin for his contributions to Gilead and to the lives of millions of people around the world." About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Keywords for this news article include: Pharmaceutical Companies, Biopharmaceuticals, Drugs and Therapies, Gilead Sciences Inc..

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
09:12a GILEAD SCIENCES : adds to CAR-T assets with Cell Design Labs buyout
01:31a GILEAD SCIENCES : Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Pati..
12/11 GILEAD SCIENCES : Today’s Research Reports on Stocks to Watch: Gilead Sciences a..
12/11 GILEAD SCIENCES : and Kite to Acquire Cell Design Labs
12/11 GILEAD SCIENCES : Hookipa raises EUR 50 million series C
12/11 GILEAD SCIENCES : acquires CDL for $567m
12/11 GILEAD SCIENCES : US stocks end higher on Friday on the back of strong jobs data
12/11 GILEAD : Kite Reveals Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta
12/10 GILEAD SCIENCES : acquires CDL for $567m
12/10 GILEAD SCIENCES : Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yes..
More news
News from SeekingAlpha
10:03a GILEAD : Avoid 2017's Frustrations
06:13a YOUR DAILY PHARMA SCOOP : Gilead Remains Long-Term Story, Argenx Rallies, Bluebi..
12/11 YOUR DAILY PHARMA SCOOP : Celgene Upside, Erytech Tumbles, Novartis Neulasta Bio..
12/10 GILEAD DOUBLES DOWN ON CAR-T : Updates To Thesis
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
Financials ($)
Sales 2017 25 816 M
EBIT 2017 15 661 M
Net income 2017 10 511 M
Debt 2017 12 742 M
Yield 2017 2,71%
P/E ratio 2017 9,75
P/E ratio 2018 12,72
EV / Sales 2017 4,33x
EV / Sales 2018 4,91x
Capitalization 99 094 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 85,7 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES1.55%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS88.38%35 831
GENMAB1.79%11 452
BLUEBIRD BIO INC172.12%9 249
EXELIXIS, INC.80.42%7 816